多発性骨髄腫患者におけるカルフィルゾミブ関連血栓小動脈症: 補足遺伝的変異の影響とエクリズマブ療法
Joana Lopes1, Vítor Fernandes1, Nuria Paulo1
1Nephrology Department, Unidade Local de Saúde São João, Porto, PRT.
Cureus
|September 2, 2025
まとめ
カルフィルゾミブ治療は稀に血栓性微血管病と急性腎臓損傷を引き起こします. エキュリズマブによる迅速な治療は,特に遺伝的傾向のある患者では,完全な回復につながる可能性があります.
科学分野:
- 腎臓科
- 血液学
- 薬理学について
背景:
- カーフィルゾミブは,再発性/耐性多発性骨髄腫に対するプロテアソーム阻害剤です.
- カーフィルゾミブは有効ですが,まれで重度の副作用があります.
- トロンボティック・マイクロアニオパシー (TMA) と急性腎損傷 (AKI) は潜在的な合併症です.
さらに関連する動画
関連する概念動画
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Drugs that Stabilize Microtubules
2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K

![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
